Kerri Fitzgerald
Articles by Kerri Fitzgerald
The approach may help inform clinical decision-making early in treatment.
The authors of the study won the 2022 SNMMI Abstract of the Year Award.
The novel artificial intelligence can produce high-quality PET/CT images while decreasing radiation exposure to ...
A study published in the European Journal of Haematology found that a diagnosis of primary myelofibrosis (MF) or ...
In patients with an unsatisfactory response to first knee replacement, the best predictor of achieving a satisfactory ...
Sickle cell disease (SCD) shortens life expectancy and leads to morbidity. Recent advancements in allogeneic ...
Alpha-globin mutations are common, and the number and type of mutated alleles will determine the severity of subsequent ...
At the all-virtual 62nd ASH Annual Meeting & Exposition, researchers presented data from an ongoing phase I/II trial ...
A study published as part of the American College of Rheumatology Annual Meeting compared denosumab versus alendronate ...
Ankit Kansagra, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center ...
A study published in Blood identified the following factors as predictive of worse outcomes for patients with multiple ...
Romosozumab produces “substantial” bone mineral density (BMD) gains at the total hip and lumbar spine within one ...
A study presented at the 2020 Society of Hematologic Oncology Annual Meeting found that the addition of ixazomib to ...
Researchers compared the efficacy of lenalidomide and dexamethasone paired with carfilzomib or bortezomib for the ...
Maintenance therapy increases survival in patients with multiple myeloma (MM) compared with observation, according to a ...
The U.S. Food and Drug Administration approved Retevmo® (selpercatinib) for three types of RET-mutated cancer: adults ...
The U.S. Food and Drug Administration (FDA) approved Lynparza® (olaparib) in combination with Avastin® (bevacizumab) ...
The U.S. Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib) for adults with metastatic non-small cell ...
Frontline tislelizumab plus chemotherapy significantly improved progression-free survival (primary endpoint) compared ...
The U.S. Food and Drug Administration (FDA) approved Braftovi® (encorafenib) in combination with cetuximab for ...
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.